fashion -WSS

fashion

author：entertainment 2025-09-04 02:37:22 - browse：8134

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： AI for drug discovery: Experts on separating hype from reality

WSS

As the dark side of IVF slowly comes into focus, even more transparency is needed

Can gargling with Listerine treat gonorrhea of the mouth?

AI for drug discovery: Experts on separating hype from reality

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Brain MRIs reveal impact of 'toxic stress' on Black children

Black vets could get higher VA benefits if race not used in lung test

focus

fashion

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

'The boss' wants server deleted: New allegations emerge in Trump indictment

How one medical school became remarkably diverse

Has Bernie Sanders reached the limit of his pharma bullying effort?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

An outrageous hospital charge: I paid $710 for an hour of babysitting

In age of alternative facts, a scholarly course on calling out crap

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Bright Health sells Medicare Advantage business to Molina

Lawmakers grill UnitedHealth CEO on Change cyberattack

entertainment

Has Bernie Sanders reached the limit of his pharma bullying effort?

The mammogram wars are not over

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Interest rates are at a 22

Lawmakers grill UnitedHealth CEO on Change cyberattack

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

explore

hotspot

leisure time

entertainment